New Daily Tablet Approved for Menopause Symptoms Offers Relief to 500,000 Women
Health officials have announced a significant breakthrough in menopause treatment, with a new daily tablet designed to alleviate hot flushes and night sweats potentially benefiting around half a million women across the UK. The non-hormonal medication, known as Fezolinetant or Veoza, has received approval from the National Institute for Health and Care Excellence for prescription on the NHS.
Targeting Women Unsuitable for Traditional HRT
This treatment is specifically intended for individuals for whom traditional hormone replacement therapy is not suitable. Many women are unable to take HRT due to existing medical conditions, including a history of blood clots or other contraindications. Additionally, some individuals choose not to use HRT despite it being the primary recommended treatment for menopausal symptoms.
The medication, manufactured by Astellas Pharma, operates by blocking specific nerve pathways in the brain responsible for triggering these common menopausal symptoms. This mechanism offers an alternative approach to symptom management that doesn't involve hormonal intervention.
NICE Approval and Patient Impact
NICE has confirmed that Fezolinetant can meaningfully reduce symptoms, and making the treatment available through the NHS will provide much-needed relief to those for whom HRT is unsuitable. Helen Knight, director of medicines evaluation at NICE, emphasized the profound impact these symptoms can have on quality of life and overall wellbeing.
"For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be," Knight stated. "The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost-effective, offering value for the taxpayer."
Clinical Monitoring and Expert Endorsement
The health spending watchdog has noted that women will need regular liver function monitoring while taking the treatment to ensure safety and efficacy. This precautionary measure is standard for many medications and helps maintain patient wellbeing during treatment.
Dr Sue Mann, national clinical director in women's health for NHS England, welcomed the approval, stating: "Symptoms of menopause including hot flushes and night sweats can affect every part of a woman's life, so this is very welcome news especially for women who are unable to or don't wish to take hormone replacement therapy."
Dr Mann added: "It's another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health."
The approval represents a significant advancement in women's healthcare, providing expanded options for managing menopausal symptoms that affect daily functioning and quality of life for many individuals.
